🇺🇸·Apr 12Research
The San Francisco Business Times honors ARCH’s Carol Suh on 40 Under 40 Class of 2026
Publisher
A
ARCH Venture Partners
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- ARCH Venture Partners
- Region
- USA
- Scope
- Research
- Published
- April 12, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on archventure.com
Leave the platform to read the original full article on the publisher site.
Source: ARCH Venture Partners
Scope: Research
Related coverage
More related coverage
PubMed — Nephrology & renal therapeutics/5h ago
From mechanism to therapeutics: targeting the mitogen-activated protein kinase 1 (MAPK1)/extracellular signal-regulated kinase 2 (ERK2) pathway in renal fibrosis.
PubMed — Nephrology & renal therapeutics/5h ago
Comparing the outcomes of non-papillary versus papillary mini-percutaneous nephrolithotomy for treatment of multiple renal stones: a prospective randomized study.
PubMed — Nephrology & renal therapeutics/5h ago
Two versus four weeks ureteral stenting prior to flexible ureteroscopy after failed primary ureteral access sheath insertion: a randomized trial.
PubMed — Nephrology & renal therapeutics/5h ago